Anti-LMNA Antibody (9Q55)

Name: Anti-LMNA Antibody (9Q55)
Brand: TargetMol
SKU: TMAH-00699
Rating: 4.5 (1 reviews)

还可以

产品编号 TMAH-00699

别名 Renal carcinoma antigen NYREN32, Renal carcinoma antigen NY REN 32, PRO1, Prelamin A/C, LMNL1, LMNC, LMN C, LMN A, LMN 1, Limb girdle muscular dystrophy 1B, LGMD1B, LFP, LDP1, Lamin C, Lamin A/C like 1, Lamin A/C, Lamin A, Lamin, IDC, HGPS, FPLD2, FPLD, FPL, EMD2, CMT2B1, CMD1A, CDDC, CDCD1, Cardiomyopathy dilated 1A, autosomal dominant, 70 kDa lamin

Anti-LMNA Antibody (9Q55) 是一种抗体，靶向 LMNA。Anti-LMNA Antibody (9Q55) 可用于 ELISA, IHC, IF, FCM, IP。

Anti-LMNA Antibody (9Q55)

还可以

产品编号 TMAH-00699 别名 Renal carcinoma antigen NYREN32, Renal carcinoma antigen NY REN 32, PRO1, Prelamin A/C, LMNL1, LMNC, LMN C, LMN A, LMN 1, Limb girdle muscular dystrophy 1B, LGMD1B, LFP, LDP1, Lamin C, Lamin A/C like 1, Lamin A/C, Lamin A, Lamin, IDC, HGPS, FPLD2, FPLD, FPL, EMD2, CMT2B1, CMD1A, CDDC, CDCD1, Cardiomyopathy dilated 1A, autosomal dominant, 70 kDa lamin

Anti-LMNA Antibody (9Q55) 是一种抗体，靶向 LMNA。Anti-LMNA Antibody (9Q55) 可用于 ELISA, IHC, IF, FCM, IP。

规格	价格	库存	数量
50 μL	¥ 1,315	5日内发货
100 μL	¥ 2,180	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

联系我们获取更多批次信息

资源下载

产品操作手册

产品介绍

生物活性

产品描述	Anti-LMNA Antibody (9Q55) is an antibody targeting LMNA. Anti-LMNA Antibody (9Q55) can be used in ELISA, IHC, IF, FCM, IP.
别名	Renal carcinoma antigen NYREN32, Renal carcinoma antigen NY REN 32, PRO1, Prelamin A/C, LMNL1, LMNC, LMN C, LMN A, LMN 1, Limb girdle muscular dystrophy 1B, LGMD1B, LFP, LDP1, Lamin C, Lamin A/C like 1, Lamin A/C, Lamin A, Lamin, IDC, HGPS, FPLD2, FPLD, FPL, EMD2, CMT2B1, CMD1A, CDDC, CDCD1, Cardiomyopathy dilated 1A, autosomal dominant, 70 kDa lamin
Ig Type	Rabbit IgG
克隆号	9Q55
交叉反应	Human
验证活性	1. IHC image of TMAH-00699 diluted at 1:115 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system. 2. IHC image of TMAH-00699 diluted at 1:115 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system. 3. Immunofluorescence staining of Hela cells with TMAH-00699 at 1:38, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L). 4. Immunoprecipitating Lamin A/C in Hela whole cell lysate Lane 1: Rabbit control IgG instead of TMAH-00699 in Hela whole cell lysate. For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000) Lane 2: TMAH-00699 (3μg) + Hela whole cell lysate (500μg) Lane 3: Hela whole cell lysate (20μg) 5. Overlay histogram showing Hela cells stained with TMAH-00699 (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then permeabilized with 0.3% Triton X-100 for 2 min. The cells were then incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-rabbit IgG (H+L) at 1/200 dilution for 1 h at 4°C. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
应用	ELISA IHC IF FCM IP
推荐剂量	IHC:1:50-1:200; IF:1:20-1:200; IP:1:200-1:1000.
抗体种类	Monoclonal
亚细胞定位	Nucleus. Nucleus envelope. Nucleus lamina. Nucleus, nucleoplasm. Nucleus matrix. Note=Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleavage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.; [Isoform C]: Nucleus speckle.
构建方式	Recombinant Antibody
纯化方式	Affinity-chromatography
性状	Liquid
缓冲液	Phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
研究背景	Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Recruited by DNA repair proteins XRCC4 and IFFO1 to the DNA double-strand breaks (DSBs) to prevent chromosome translocation by immobilizing broken DNA ends. Plays an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics. Required for normal development of peripheral nervous system and skeletal muscle and for muscle satellite cell proliferation. Required for osteoblastogenesis and bone formation. Also prevents fat infiltration of muscle and bone marrow, helping to maintain the volume and strength of skeletal muscle and bone. Required for cardiac homeostasis. Prelamin-A/C can accelerate smooth muscle cell senescence. It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence.